Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in End-Stage Renal Disease Patients on Chronic Hemodialysis: A Single-Center Study
<i>Background and Objectives</i>: In addition to a suboptimal and rapidly diminishing response to the coronavirus disease 2019 (COVID-19) vaccine, hemodialysis (HD) patients are at risk for developing a severe COVID-19 infection. In 2022, the combination of cilgavimab and tixagevimab (Evusheld, Astr...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2023-12-01
|
| Col·lecció: | Medicina |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1648-9144/59/12/2109 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|